Lift for Roche as Alnylam drug lowers blood pressure

Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po

Alnylam showcases long-acting amyloid drug at AAIC

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially

Scopus Bio preps trials of gene-silencing immuno-oncology dr...

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.

Alnylam gets CHMP backing for second gene-silencing drug Giv...

Alnylam to file rare kidney disease drug after trial win

After years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing to file a rare kidney disease drug with the FDA, after two previous approvals.

Roche swoops on Dicerna’s gene-silencing hepatitis B drug